Arrowhead Research | ARWR - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Anika Therapeutics USD 146.8M 867K 2025-09
Arrowhead Research USD 223.22M 10.86M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Novartis USD 9.86B 115M 2025-09
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
TG Therapeutics USD 142.08M 9.74M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xencor USD 81.86M 13.35M 2025-12